CEO Pascal Soriot via Getty Images

As­traZeneca's jug­ger­naut PARP play­er Lyn­parza scoops up an­oth­er dom­i­nant win in PhI­II as the FDA adds a 'break­through' for Calquence

As­traZeneca’s on­col­o­gy R&D group un­der José Basel­ga keeps churn­ing out hits.

Wednes­day morn­ing the phar­ma gi­ant and their part­ners at Mer­ck part­ed the cur­tains on a suc­cess­ful read­out for their Phase III PAO­LA-1 study, demon­strat­ing sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in pro­gres­sion-free sur­vival for women with ovar­i­an can­cer in a first-line main­te­nance set­ting who added their PARP Lyn­parza to Avastin. This is their sec­ond late-stage suc­cess in ovar­i­an can­cer, which will help stave off ri­vals like GSK.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.